In the media
NLS Pharma Named Winner Of A Prestigous 2016 Healthcare & Life Sciences Award
NLS Pharma Group (NLS) announced today that it has been named 'Most Outstanding in Clinical-Stage Drug Development'.
The Healthcare and Life Science Awards celebrate the most innovative and successful projects carried out around the world over the past 12 months. NLS impressed the panel of judges at Corporate LiveWire in its development of a non-amphetaminic stimulant for ADHD.
"It is gratifying to see that NLS, and the hard work and dedication of our team, has been recognized by Corporate LiveWire," noted Alex Zwyer, CEO of NLS Pharma Group. "Clinicians and patients need effective and tolerable non-stimulant alternative medications to treat ADHD. Additionally, at risk populations need safe and non-addictive treatment options. Our current program creates a unique opportunity for the safe and successful treatment of ADHD in adults. We are proud to be making a difference," adds Nelson Handal, MD - Chief Medical Officer of NLS.
About NLS Pharma
NLS Pharma (NLS) is a Swiss based biotech group focusing on the repurposing of established and (cost-) effective drug/chemical compounds to treat ADHD, sleep disorders and cognitive impairment.
NLS is a fully privately owned enterprise managed by a top level team of experts who have demonstrated their value and experience with Big Pharma companies. They work closely with renowned AD-HD and sleep related disorders opinion leaders.
On August 29, 2016 NLS announced the initiation of its "Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)". The company expects Top-Line Phase II results for NLS1/Mazindol in late spring 2017.
On July 11, 2016 NLS announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) for Mazindol for the treatment of Narcolepsy.
On October 9, 2015, an ODD was granted by the European Commission to NLS for Mazindol within the same indication. Series-A financing was successfully completed on August 31, 2015, to secure full development of NLS-1 (Mazindol) up to Proof-of-Concept in ADHD.
First published on http://www.prnewswire.com/